ArticlePloS one2026
Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe decision on appropriate adjuvant treatment for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative (HER2-) early breast cancer (eBC) is sometimes challenging. Genomic assays have improved individualized treatment decisions by providing information on the genomic risk of tumors. The Oncotype DX assay (ODX) is both prognostic and predictive of chemotherapy benefit. This study aimed to evaluate the implementation process of the ODX into clinical practice, the impact of ODX on adjuvant chemotherapy treatment decisions and conduct a cost impact analysis. PATIENTS AND
methodsA retrospective study at Tampere University Hospital included 129 patients with HR + , HER2- eBC tested with ODX between September 2021 and September 2023. Treatment decisions as well as adjuvant chemotherapy (CT) costs, associated health provider costs, and societal costs were projected.
resultsODX testing significantly altered CT recommendations by reducing unnecessary CT for 73% of the study patients. With ODX testing, the cost impact analysis revealed partial cost savings for the health care provider due to reduced CT administration. From a societal perspective, the use of ODX resulted in substantial savings largely attributed to the maintenance of work productivity among working-aged and employed patients.
conclusionThis study highlights the importance of streamlined testing processes and the need for clinician training in interpreting test results in a real-world setting. In addition, the findings underscore the role of ODX in enhancing personalized treatment in HR + , HER2- eBC while reducing overtreatment. The cost analysis indicates substantial cost savings with ODX testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.